UnknownPhase 2NCT05969743

Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rabin Medical Center
Principal Investigator
Moshe Yeshurun, MD
Institution of Hematology, Rabin Medical Center
Intervention
Letermovir(drug)
Enrollment
42 target
Eligibility
18-120 years · All sexes
Timeline
20232025

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05969743 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials